<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831960</url>
  </required_header>
  <id_info>
    <org_study_id>171-7151-202</org_study_id>
    <nct_id>NCT01831960</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris</brief_title>
  <official_title>An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intrepid Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intrepid Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression
      potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve
      hours for two weeks, in subjects with acne vulgaris ages 12 years or older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HPA Axis Response to Cosyntropin</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PK profiles of cortexolone 17α-propionate and cortexolone</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>Concentration-time profiles of cortexolone 17α-propionate and its metabolite, cortexolone, in plasma.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Cortexolone 17α-Propionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical cream, 1.0% concentration, applied every twelve hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cortexolone 17α-propionate</intervention_name>
    <arm_group_label>Cortexolone 17α-Propionate</arm_group_label>
    <other_name>CB-03-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has moderate to severe facial acne vulgaris as determined by the
             Investigator's Global Assessment (IGA) and obvious acne on the chest and/or back at
             study start.

          -  Subject has facial acne vulgaris (including the nose) with a minimum number of
             inflammatory lesions (papules, pustules, and nodules/cysts) and a minimum number of
             non-inflammatory lesions (open and closed comedones) at study start.

          -  Females must be post-menopausal, surgically sterile or using highly effective birth
             control methods with a negative urine pregnancy test (UPT) at study start.

          -  Subject must be in general good health in the opinion of the investigator, with normal
             renal function, based on screening physical examination, medical history, and clinical
             laboratory values.

        Exclusion Criteria:

          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

          -  Subject is 12-20 years of age and has a Body Mass Index (BMI) for age percentile &gt;
             85%.

          -  Subject is &gt; 20 years of age and has a BMI &gt; 32.0 kg/m2.

          -  Subject has used tobacco, smoking cessation products, or products containing nicotine
             within three months prior to study start.

          -  Except for the use of contraceptives, subject has used any prescription drug or herbal
             product within 14 days prior to dosing, any non-prescription drug or vitamin or
             mineral supplements within 7 days prior to study start; any known enzyme-inducer,
             enzyme-inhibitor, or reported chronic exposure to enzyme-inducers such as paint
             solvents or pesticides within 30 days of study start.

          -  Subject has used topical anti-acne medications containing retinoids such as
             tazarotene, adapalene or tretinoin, within four weeks of study start.

          -  Subject has used the following systemic anti-acne medications: antibiotics within two
             weeks of study start, spironolactone within four weeks of study start, or retinoid
             therapy within three months of study start.

          -  Subject has any skin or medical condition, including facial hair that could interfere
             with the evaluation of the test article or requires the use of interfering topical or
             systemic therapy.

          -  Subject has the need or plans to be exposed to artificial tanning devices or excessive
             sunlight during the study.

          -  Subject has used light treatments, microdermabrasion or chemical peels to the face,
             chest and back within eight weeks of study start.

          -  Subject cannot avoid any type of strenuous exercise (swimming, running, team sports,
             etc.,) or the use of hot tubs/saunas from study start to the end of the study.

          -  Subject has received an investigational drug or been treated with an investigational
             device within 30 days prior to study start.

          -  Subject is currently enrolled in an investigational drug or device study.

          -  Subject has used topical corticosteroids (including inhaled and intranasal
             corticosteroids) within two weeks of study start.

          -  Subject has used systemic corticosteroids (including intramuscular and intralesional
             injections) within four weeks of study start.

          -  Subject has an irregular sleep schedule or works night shifts.

          -  Subject has experienced significant blood loss within 60 days or has donated plasma
             within 72 hours prior to study start.

          -  Subject tests positive at Screening for human immunodeficiency virus (HIV) or is known
             to be seropositive for HIV.

          -  Subject tests positive at Screening for hepatitis B surface antigen, hepatitis C
             antibody or has a history of a positive result.

          -  Subject had major surgery within 30 days prior to study start or plans to have surgery
             during the study.

          -  Subject has participated in a previous CB-03-01 study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syd Dromgoole, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Clinical Trials, Inc.</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Corp.</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <disposition_first_submitted>March 27, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2015</disposition_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrepid</keyword>
  <keyword>cortexolone</keyword>
  <keyword>cortexolone 17α-propionate</keyword>
  <keyword>anti-androgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

